CEFOXITIN SODIUM - Generic Drug Details

What are the generic drug sources for cefoxitin sodium and what is the scope of freedom to operate?

Cefoxitin sodium is the generic ingredient in seven branded drugs marketed by Acs Dobfar, Acs Dobfar Spa, Fresenius Kabi Usa, Hikma, Hikma Farmaceutica, Hospira Inc, B Braun, Norvium Bioscience, Merck, and Samson Medcl, and is included in eighteen NDAs. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for cefoxitin sodium. Six suppliers are listed for this compound.

Summary for CEFOXITIN SODIUM

US Patents:	0
Tradenames:	7
Applicants:	10
NDAs:	18
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	70
Clinical Trials:	1
Patent Applications:	2,692
What excipients (inactive ingredients) are in CEFOXITIN SODIUM?	CEFOXITIN SODIUM excipients list
DailyMed Link:	CEFOXITIN SODIUM at DailyMed

Recent Clinical Trials for CEFOXITIN SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alphacait, LLC	Phase 2
Haining Health-Coming Biotech Co., Ltd.	Phase 2

See all CEFOXITIN SODIUM clinical trials

Pharmacology for CEFOXITIN SODIUM

Drug Class

Cephalosporin Antibacterial

Medical Subject Heading (MeSH) Categories for CEFOXITIN SODIUM

Anti-Bacterial Agents

Anatomical Therapeutic Chemical (ATC) Classes for CEFOXITIN SODIUM

J01DC	Second-generation cephalosporins
J01D	OTHER BETA-LACTAM ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for CEFOXITIN SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma Farmaceutica	CEFOXITIN	cefoxitin sodium	INJECTABLE;INJECTION	065239-001	Mar 2, 2010	AP	RX	No	No
Hikma Farmaceutica	CEFOXITIN	cefoxitin sodium	INJECTABLE;INJECTION	065238-002	Mar 12, 2010	AP	RX	No	No
Acs Dobfar Spa	CEFOXITIN	cefoxitin sodium	INJECTABLE;INJECTION	065467-001	Aug 31, 2011		DISCN	No	No
Norvium Bioscience	MEFOXIN	cefoxitin sodium	INJECTABLE;INJECTION	062757-001	Jan 8, 1987		DISCN	No	No
Hikma Farmaceutica	CEFOXITIN	cefoxitin sodium	INJECTABLE;INJECTION	065238-001	Mar 12, 2010	AP	RX	No	No
Merck	MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER	cefoxitin sodium	INJECTABLE;INJECTION	050581-003	Sep 20, 1984		DISCN	Yes	No

CEFOXITIN SODIUM Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Cefoxitin Sodium

Introduction

Cefoxitin sodium, a cephalosporin antibiotic, is widely used to treat bacterial infections and prevent surgical site infections. The market for cefoxitin sodium is experiencing significant growth, driven by several key factors.

Market Size and Growth Projections

The cefoxitin sodium for injection market has seen rapid and substantial growth in recent years. As of 2023, the market size was valued at several billion USD, and it is anticipated to reach even higher figures by 2031. This growth is attributed to the increasing demand for effective antibiotics, particularly in the face of rising antimicrobial resistance[1].

Segmentation and Market Outlook

The market is segmented based on type (0.5g/Piece, 1.0g/Piece, 2.0g/Piece) and application (Hospital Pharmacy, Retail Pharmacy), as well as geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa). Each segment is expected to contribute to the overall growth, with hospital pharmacies being a major driver due to the high volume of surgical procedures and infections treated in these settings[1].

Drivers of Market Growth

Several factors are driving the growth of the cefoxitin sodium market:

• Increasing Incidence of Bacterial Infections: The rise in bacterial infections, especially those caused by multi-resistant pathogens, has heightened the demand for effective antibiotics like cefoxitin sodium[2].
• Pre-Surgical Use: Cefoxitin sodium is often administered before surgery to prevent infections, contributing to its widespread use in surgical settings[3].
• Extended Shelf Life: Recent studies have supported the extension of the shelf life of reconstituted cefoxitin sodium, making it more convenient for storage and use, which can further boost its market[2].

Competitive Scenario

The market for cefoxitin sodium is competitive, with several key players such as Yangtze River Pharmaceutical Group, ShenZhen Lijian Pharmaceutical, Hainan Guangshengyu Pharmaceutical, and others. These companies are profiled based on their product offerings, market entry year, and other relevant factors. The competitive landscape is dynamic, with companies focusing on improving product quality, stability, and distribution networks[1].

Geographical Analysis

The market is geographically diverse, with significant growth expected in regions like Asia-Pacific and North America. The Asia-Pacific region is particularly promising due to its large population, increasing healthcare expenditure, and growing awareness of antibiotic treatments[1].

Economic and Regulatory Factors

The economic landscape, including national GDP and healthcare policies, plays a crucial role in shaping the market. Regulatory frameworks, such as those related to drug stability and shelf life, also influence the market dynamics. For instance, the extension of shelf life for reconstituted cefoxitin sodium, as supported by recent studies, can lead to cost savings and improved supply chain efficiency[2].

Challenges and Opportunities

Despite the growth, the market faces several challenges:

• Antimicrobial Resistance: The increasing resistance to antibiotics poses a significant threat to the market.
• Regulatory Hurdles: Strict regulatory requirements and varying guidelines across different regions can affect market growth.
• Competition: The presence of other antibiotics and generic versions can compete with cefoxitin sodium.

However, there are also opportunities:

• Emerging Markets: Growing healthcare needs in developing countries offer significant market potential.
• Research and Development: Continuous R&D in improving the stability and efficacy of cefoxitin sodium can enhance its market position[1][2].

Financial Trajectory

The financial trajectory of the cefoxitin sodium market is promising, with projected strong growth rates from 2023 to 2031. The market is expected to expand significantly, driven by increasing demand and favorable market conditions. Here are some key financial highlights:

• Revenue Growth: The market is anticipated to reach several billion USD by 2031, indicating a substantial increase from its current value.
• Investment Prospects: The market offers attractive investment opportunities, particularly in the areas of R&D and distribution networks[1].

Company Profiles and Market Strategies

Key companies in the market are focusing on various strategies to maintain and enhance their market share. These include:

• Product Diversification: Companies are diversifying their product portfolios to include different dosages and formulations of cefoxitin sodium.
• Market Expansion: Expanding into new geographical regions, especially emerging markets, is a key strategy.
• Partnerships and Collaborations: Forming partnerships with healthcare providers and distributors to improve market penetration[1].

Consumer Behavior and Preferences

Consumer behavior, particularly in the healthcare sector, is influenced by the effectiveness and safety of the medication. Cefoxitin sodium's reputation for treating a wide range of bacterial infections and its pre-surgical use have made it a preferred choice among healthcare professionals. Patient compliance and satisfaction also play a crucial role in driving market demand[3].

Side Effects and Safety Considerations

While cefoxitin sodium is generally safe, it can cause side effects such as diarrhea, skin reactions, and in rare cases, more severe reactions like seizures. These factors must be considered in the prescribing and administration of the drug, and companies must ensure clear labeling and patient education to mitigate these risks[3].

Key Takeaways

• The cefoxitin sodium market is experiencing rapid growth driven by increasing demand for effective antibiotics.
• The market is segmented by type, application, and geographical region, with hospital pharmacies being a significant segment.
• Key drivers include the rise in bacterial infections, pre-surgical use, and extended shelf life.
• The competitive landscape is dynamic, with several key players focusing on product quality and distribution.
• Economic and regulatory factors, as well as challenges like antimicrobial resistance, need to be addressed.

FAQs

Q: What is the primary use of cefoxitin sodium? A: Cefoxitin sodium is used to treat bacterial infections in various parts of the body and is also administered before certain types of surgery to prevent infections[3].

Q: Which regions are expected to drive the growth of the cefoxitin sodium market? A: The Asia-Pacific and North America regions are expected to be significant drivers of market growth due to their large populations and increasing healthcare expenditures[1].

Q: What are the key challenges facing the cefoxitin sodium market? A: The market faces challenges such as antimicrobial resistance, regulatory hurdles, and competition from other antibiotics and generic versions[1][2].

Q: How does the extended shelf life of cefoxitin sodium impact the market? A: The extended shelf life of reconstituted cefoxitin sodium can lead to cost savings, improved supply chain efficiency, and increased convenience for storage and use, thereby boosting market demand[2].

Q: Which companies are major players in the cefoxitin sodium market? A: Key companies include Yangtze River Pharmaceutical Group, ShenZhen Lijian Pharmaceutical, Hainan Guangshengyu Pharmaceutical, and others[1].

Cited Sources:

1. Market Research Intellect: Cefoxitin Sodium for Injection Market Size, Scope And Forecast Report.
2. BMJ: Systematic review of room temperature stability of key beta-lactam antibiotics.
3. Mayo Clinic: Cefoxitin (intravenous route) - Mayo Clinic.